Women with suspected preeclampsia were diagnosed sooner and had fewer serious adverse outcomes when clinicians had results of a test that detects circulating concentration of placental growth factor (PIGF), reported a real-world trial in the Lancet.
The study enrolled 1035 women with suspected pre-eclampsia at 11 hospitals in the United Kingdom. At the study’s start, PIGF measurements were obtained from all participants. But treating clinicians didn’t receive test results until their hospital began the intervention, which revealed and integrated PIGF results into a clinical management algorithm that recommended targeted enhanced surveillance. Hospitals were randomly assigned to start the intervention at different times. Ultimately, 436 women received usual care (concealed testing) and 576 received the intervention (revealed testing).
Slomski A. Placental Growth Factor Testing for Faster Preeclampsia Diagnosis. JAMA. 2019;321(24):2396. doi:10.1001/jama.2019.8397
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: